@article{78cdf827689c49f4bac2045d771ae7e4,
title = "Adulthood cognitive trajectories over 26 years and brain health at 70 years of age: findings from the 1946 British Birth Cohort",
abstract = "Few studies can address how adulthood cognitive trajectories relate to brain health in 70-year-olds. Participants (n = 468, 49% female) from the 1946 British birth cohort underwent 18F-Florbetapir PET/MRI. Cognitive function was measured in childhood (age 8 years) and across adulthood (ages 43, 53, 60–64 and 69 years) and was examined in relation to brain health markers of β-amyloid (Aβ) status, whole brain and hippocampal volume, and white matter hyperintensity volume (WMHV). Taking into account key contributors of adult cognitive decline including childhood cognition, those with greater Aβ and WMHV at age 70 years had greater decline in word-list learning memory in the preceding 26 years, particularly after age 60. In contrast, those with smaller whole brain and hippocampal volume at age 70 years had greater decline in processing search speed, subtly manifest from age 50 years. Subtle changes in memory and processing speed spanning 26 years of adulthood were associated with markers of brain health at 70 years of age, consistent with detectable prodromal cognitive effects in early older age.",
keywords = "Amyloid, Brain health, Brain volume, Cognition, Cognitive decline, Life course",
author = "Sarah-Naomi James and Nicholas, {Jennifer M.} and Kirsty Lu and Ashvini Keshavan and Lane, {Christopher A.} and Thomas Parker and Buchanan, {Sarah M.} and Keuss, {Sarah E.} and Heidi Murray-Smith and Andrew Wong and Cash, {David M.} and Malone, {Ian B.} and Josephine Barnes and Sudre, {Carole H.} and William Coath and Marc Modat and Sebastien Ourselin and Crutch, {Sebastian J.} and Diana Kuh and Fox, {Nick C.} and Schott, {Jonathan M.} and Marcus Richards",
note = "Funding Information: This study is principally funded by grants from Alzheimer's Research UK (ARUK-PG2014-1946, ARUK-PG2017-1946), the Medical Research Council Dementias Platform UK (CSUB19166), and the Wolfson Foundation (PR/ylr/18575). The genetic analyses are funded by the Brain Research Trust (UCC14181). Florbetapir amyloid tracer is kindly provided by AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly) who had no part in the design of the study. The National Survey of Health and Development is funded by the Medical Research Council (MC_UU_10019/1, MC_UU_10019/3). The authors thank the study members who helped in the design of the study through focus groups, and to all the participants for both their contributions to Insight 46 and for their commitments to research over the last seven decades. We are grateful to the radiographers and nuclear medicine physicians (Professor Ashley Groves, Dr Jamshed Bomanji, Dr Irfan Kayani) at the UCL Institute of Nuclear Medicine, and to the staff at the Leonard Wolfson Experimental Neurology Centre at UCL. We would like to acknowledge Dan Marcus and Rick Herrick for assistance with XNAT, Dr Philip Curran for assistance with data sharing with the MRC Unit for Lifelong Health and Ageing and the DRC trials team for assistance with imaging QC. Funding Information: This study is principally funded by grants from Alzheimer's Research UK ( ARUK-PG2014-1946 , ARUK-PG2017-1946 ), the Medical Research Council Dementias Platform UK ( CSUB19166 ), and the Wolfson Foundation ( PR/ylr/18575 ). The genetic analyses are funded by the Brain Research Trust ( UCC14181 ). Florbetapir amyloid tracer is kindly provided by AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly) who had no part in the design of the study. The National Survey of Health and Development is funded by the Medical Research Council ( MC_UU_10019/1 , MC_UU_10019/3 ). Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2023",
month = feb,
day = "1",
doi = "https://doi.org/10.1016/j.neurobiolaging.2022.10.003",
language = "English",
volume = "122",
pages = "22--32",
journal = "Neurobiology of aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
}